Amcad Biomed (ROCO:4188) LT-Debt-to-Total-Asset : 0.01 (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Amcad Biomed LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Amcad Biomed's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.01.

Amcad Biomed's long-term debt to total assets ratio declined from Dec. 2023 (0.02) to Dec. 2024 (0.01). It may suggest that Amcad Biomed is progressively becoming less dependent on debt to grow their business.

Amcad Biomed LT-Debt-to-Total-Asset Historical Data

The historical data trend for Amcad Biomed's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amcad Biomed LT-Debt-to-Total-Asset Chart

Amcad Biomed Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.01

0.02

0.01

Amcad Biomed Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.02	0.02	0.02	0.01	0.01

Amcad Biomed LT-Debt-to-Total-Asset Calculation

Amcad Biomed's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	5.724	/	694.873
	=	0.01

Amcad Biomed's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	5.724	/	694.873
	=	0.01

Amcad Biomed (ROCO:4188) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Amcad Biomed LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Amcad Biomed's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Amcad Biomed Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Amcad Biomed Corp (ROCO:4188) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 167, Fuxing North Road, 5th Floor, Zhongshan District, Taipei, TWN, 104

Website

https://www.amcad.com.tw

Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, AmCAD-UV, AmCAD and AmCAD-UO. The company's geographical segments include Taiwan, China, and other countries, out of which the majority of the revenue is generated from Europe. The company has two segments: Medical diagnostic software: which is responsible for the development and sales of smart medical imaging diagnostic software device and Precision medical equipment: which is responsible for research, development, manufacturing and sales of high-end ultrasonic probes.

Amcad Biomed Headlines

No Headlines